Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 11
Submit an article Journal homepage
123
Views
9
CrossRef citations to date
0
Altmetric
Editorial

Palivizumab in congenital heart disease: should international guidelines be revised?

Joseph M Geskey Pennsylvania State University College of Medicine, Pennsylvania State Children's Hospital, Division of Pediatric Hospital Medicine, Department of Pediatrics, 500 University Drive, PO Box 850, Hershey, PA 17033-0850, USA +1 717 531 5606; +1 717 531 0648; [email protected]
, DO,
Neal J Thomas Pennsylvania State University College of Medicine, Pennsylvania State Children's Hospital, Division of Critical Care Medicine, Department of Pediatrics and Health Evaluation Sciences, Hershey, PA, USA
, MD, MSc &
Gretchen L Brummel Pennsylvania State University College of Medicine, Pennsylvania State Children's Hospital, Department of Pediatrics and Pharmacy, Hershey, PA, USA
, PharmD
Pages 1615-1620 | Published online: 26 Oct 2007

Bibliography

  • THOMPSON WW, SHAY DK, WEINTRAUB E et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289:179-186.
  • SHAY DK, HOLMAN RC, NEWMAN RD, LIU LL, STOUT JW, ANDERSON LJ: Bronchiolitis-associated hospitalizations among US children, 1980 – 1996. JAMA (1999) 282:1440-1446.
  • SHAY DK, HOLMAN RC, ROOSEVELT GE, CLARKE MJ, ANDERSON LJ: Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979 – 1997. J. Infect. Dis. (2001) 183:16-22.
  • MACDONALD NE, HALL CB, SUFFIN SC, ALEXSON C, HARRIS PJ, MANNING JA: Respiratory syncytial virus infection in infants with congenital heart disease. N. Engl. J. Med. (1982) 307:397-400.
  • ALTMAN CA, ENGLUND JA, DEMMLER G et al.: Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening: Pediatr. Cardiol. (2000) 21:433-438.
  • FELTES TF, CABALKA AK, MEISSNER HC et al.; for the CARDIAC SYNAGIS STUDY GROUP: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. (2003) 143:532-540.
  • CHIN J, MAGOFFIN RL, SHEARER LA, SCHIEBLE JH, LENNETTE EH: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. (1969) 89:449-463.
  • FULGINITI VA, ELLER JJ, SIEBER OF, JOYNER JW, MINAMITANI M, MEIKLEJOHN G: Respiratory virus immunization. I. A field trial of two inactivated respirator virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. (1969) 89:435-448.
  • SIMOES EA, SONDHEIMER HM, TOP FH et al.; and the CARDIAC STUDY GROUP: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J. Pediatr. (1998) 133:492-499.
  • ROBBINS JM, TILFORD JM, GILLASPY SR et al.: Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis. Ambul. Pediatr. (2002) 2:444-448.
  • RIETVELD E, VERGOUWE Y, STEYERBERG EW, HUYSMAN MWA, DE GROOT R, MOLL HA; for the RSV STUDY GROUP SOUTHWEST NETHERLANDS: Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr. Infect. Dis. J. (2006) 25:201-207.
  • PRAIS D, DANINO D, SCHONFELD T, AMIR J; for the ISRAELI RSV MONITORING GROUP: Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest (2005) 128:2765-2571.
  • WANG EEL, LAW BJ, ROBINSON JL et al.: PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics (1997) 99:E9.
  • BOYCE TG, MELLEN BG, MITCHEL EF, WRIGHT PF, GRIFFIN MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr. (2000) 137:865-870.
  • DUPPENTHALER A, AMMANN RA, GORGIEVSKI-HRISOHO M, PFAMMATTER J-P, AEBI C: Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch. Dis. Child (2004) 89:961-965.
  • ERIKSSON M, BENNET R, ROTZéN-ÖSTLUND M, VON SYDOW M, ZWEYBERG WIRGART B: Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. (2002) 91:593-598.
  • MEBERG A, BRUU A-L: Respiratory syncytial virus infections in congenital heart defects – hospitalizations and costs. Acta Paediatr. (2006) 95:404-406.
  • MEDRANO C, GARCIA-GUERETA L, GRUESO J et al.: Respiratory infection in congenital heart disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC epidemiologic study. Cardiol. Young (2007) 17:360-371.
  • KONGPHATTHANAYOTHIN A, WONG PC, SAMARA Y et al.: Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit. Care Med. (1999) 27:1974-1981.
  • MOLER FW, KHAN AS, MELIONE JN, CUSTER JR, PALMISANO J, SHOPE TC: Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit. Care Med. (1992) 20:1406-1413.
  • BUCKINGHAM SC, QUASNEY MW, BUSH AJ, DEVINCENZO JP: Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr. Crit. Care Med. (2001) 2:318-323.
  • HILL SR, MITCHELL AS, HENRY DA: Problems with interpretation of pharmacoeconomic analyses: a review of submissions to the Australian pharmaceutical benefits scheme. JAMA (2000) 283:2116-2121.
  • KAMAL-BAHL S, DOSHI J, CAMPBELL J: Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch. Pediatr. Adolesc. Med. (2002) 156:1034-1041.
  • SIMOES EAF, GROOTHUIS JR, CARBONELL-ESTRANY X et al.; THE PALIVIZUMAB LONG-TERM RESPIRATORY OUTCOMES STUDY GROUP: Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurring wheezing. J. Pediatr. (2007) 151:34-42.
  • GESKEY JM, THOMAS NJ, BRUMMEL GL: Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV). Biol. Targets Ther. (2007) 1:33-43.
  • MARTINEZ FD: Heterogeneity of the association between lower respiratory illness in infancy and subsequent asthma. Proc. Am. Thorac. Soc. (2005) 2:157-161.
  • YOUNT LE, MAHLE WT: Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics (2004) 114:1606-1611.
  • WU H, PFARR DS, JOHNSON S et al.: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. (2007) 368: 652-665.
  • MEJÍAS A, CHÁVEZ-BUENO S, RÍOS AM et al.: Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob. Agents Chemother. (2004) 48:1811-1822.
  • MOORE ML, PEEBLES RS Jr: Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol. Ther. (2006) 112:405-424.
  • TULLOH RMR, FELTES TF: The European forum for clinical management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital heart disease. Cardiol. Young (2005) 15:274-278.
  • NAVAS L, WANG E, DE CARVALHO, ROBINSON J; THE PEDIATRIC INVESTIGATORS COLLABORATIVE NETWORK ON INFECTIONS IN CANADA: Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J. Pediatr. (1992) 121:348-354.
  • MÜHLEMANN K, UELINGER DE, BÜCHI W, GORGIEVSKI M, AEBI C: The prevalence of penicillin-non-susceptible Streptococcus pneumoniae among children aged < 5 years correlates with the biannual epidemic activity of respiratory syncytial virus. Clin. Microbiol. Infect. (2006) 12:873-879.
  • TERLETSKAIA-LADWIG E, ENDERS G, SCHALASTA G, ENDERS M: Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. BMC Infect. Dis. (2005) 5:20.
  • WARIS M: Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J. Infect. Dis. (1991) 163:464-469.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.